AN fell -9.38% (-$18.32) to about $177 during regular market hours, versus a $195.37 prior close. The decline was driven by cautious commentary from CFO Tom Szlosek at the Morgan Stanley Laguna Conference.

INO gained +7.83% during regular trading hours, rising to $1.24 from a prior-session close of $1.15. The advance reverses a weeklong slide that took shares from $1.28 down to $1.15, suggesting a technical rebound in a volatile small-cap biotech.

TPST is down roughly -25.6% to about $0.90 in Thursday's regular session, giving back a large portion of the previous session's gain. On Wednesday the stock closed up +60.18% at $1.21 (intraday high $1.48) after Tempest announced an exclusive option to license Senlang's CD7-targeted lentiviral in vivo CAR-T platform, including a BCMA/GPRC5D Phase 1 candidate.

SiTime (SITM) is up +9.59% to roughly $601.52, rebounding from Wednesday's close of $548.90. The gain unfolded during regular session trading on Thursday, with shares surging roughly +9% in early action.

MasTec (MTZ) fell roughly -7.3% during regular trading hours, sliding from a $225.62 prior close to about $209.16. The decline came amid a broad market risk-off session, with no single company-specific headline driving the intraday move.

GSUN fell roughly -20% during Thursday's regular session, trading near $0.24 versus the prior close of $0.30. The drop unwinds the prior session's +30% speculative surge, when shares spiked to an intraday high of $0.48 on ~59.6M shares of turnover.

NAMI fell -34.94% during regular trading, dropping from $3.12 to about $2.03, reversing much of a two-day surge. The selloff follows a roughly +73% spike (+26.67% then +36.84%) triggered by its Sept. 15 AIGC micro-drama deal announcement.

DLXY is down -56.33% today, trading near $1.00 versus Wednesday's $2.29 close, during regular market hours as it gives back most of yesterday's +451.81% surge. The prior-day spike was fueled by a non-binding letter of intent to acquire up to 48% of Tarbagatay Munay, operator of Kazakhstan's Sarybulak Oil Field, on heavy retail-driven volume (~244M shares vs. ~293K average).

SNYR fell roughly -61.37% during regular trading, dropping from its prior close of $0.2744 to about $0.106. The decline unwinds a +233% speculative spike on Sept. 16, when volume surged to over 1 billion shares.

LGVN plunged about -56% to roughly $2.94 from a prior close of $6.68, with the move hitting during the after-hours session following a trading halt. The primary catalyst: the Phase 2b ELPIS II trial of cell therapy laromestrocel in hypoplastic left heart syndrome missed its primary endpoint of change in right ventricular ejection fraction at Month 12 (p=0.8336).

SURG rallied +28.01% during the regular session to about $0.18, up from the prior close of $0.1439. Primary catalyst: SurgePays signed a non-binding letter of intent with LowWeeklyPayments to form a joint venture scaling its smartphone rent-to-own program past 100 existing dealers.

MNOV jumped +29.76% to $3.27 during regular trading, up from a $2.52 prior-session close. The primary catalyst was Roth/MKM initiating coverage with a Buy rating and a $6.00 price target, citing ibudilast's (MN-166) potential in ALS.

USDE surged +46.29% to about $9.07 during regular trading on Sept. 17, up from a $6.20 prior-session close. The rally followed a Form 8-K filing disclosing that Ethena Foundation agreed to permanently waive all lock-ups on StablecoinX's roughly 3 billion ENA tokens, effective Oct. 5, 2026.

AEHL is up +52.49% intraday, trading near $14.06 during regular Nasdaq session hours, extending Wednesday's +78.7% surge. Primary catalyst: confirmation of the closing of a $6.0 million (≈$5.97 million net) 8.00% convertible promissory note offering to fund Kylin Cloud's China livestreaming e-commerce expansion.

TURB jumped roughly +59.55% intraday to about $1.42, up from its $0.8935 prior-session close, on sharply elevated volume. The move unfolded during regular trading after premarket strength in this thinly traded microcap.

KXIN surged +93.81% to roughly $2.19, up from the prior session's $1.13 close, during Thursday's regular session. Primary catalyst: a 6-K filing disclosed first-half 2026 results showing total revenue jumped about +602% to $667,000, driven by Hong Kong car sales through its Jet Sound HK unit.

DAIC surged +136.32% during Thursday's regular session, climbing from a $2.01 prior close to roughly $4.75. Primary catalyst: a binding agreement to acquire electric-vehicle car-sharing platform Envoy Technologies for $65 million in equity at $6.00 per share.

DTSS surged roughly +221% intraday, climbing from a $0.5912 prior close to about $1.90 during Thursday's regular session. The jump occurred in market hours on explosive, well-above-average volume, not in premarket or after-hours trading.

MRNA is up +9.88% to roughly $160 during the regular session, versus a prior close of $145.62. Primary catalyst: positive Phase 3 results for the personalized mRNA cancer vaccine intismeran autogene, used with Merck's Keytruda, in high-risk melanoma — the first late-stage mRNA oncology success.

DSP is trading down roughly -15.93% to about $10.40 versus the prior session close of $12.37, extending pressure that began in Wednesday's after-hours session. The decline is being driven by a newly disclosed 8.5 million-share secondary offering of Class A stock by a selling stockholder, creating a near-term supply overhang.